| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/20/2010 | WO2010056399A1 Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| 05/20/2010 | WO2010056144A2 Foxp3+ natural kiler t-cells and the treatment of immune related diseases |
| 05/20/2010 | WO2010055929A1 Novel hsp90-targeted anti-cancer chimeric peptide |
| 05/20/2010 | WO2010055894A1 Organic arsenic-containing compound, and composition for inhibiting growth of tumor comprising the compound |
| 05/20/2010 | WO2010055711A1 Peptide composition for saving the life of sirs patient |
| 05/20/2010 | WO2010055473A1 Methods of treating tumor cells using rhcc protein, fragment or variant |
| 05/20/2010 | WO2010055358A1 Suppression of cancer |
| 05/20/2010 | WO2010054807A1 Protein with promoting effects for axonal growth of neurons of central nervous system |
| 05/20/2010 | WO2010054667A1 Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases |
| 05/20/2010 | WO2010054528A1 Quinazoline compounds |
| 05/20/2010 | WO2010054503A1 Anticoagulant polypeptides and uses thereof |
| 05/20/2010 | WO2010054446A1 Combination of two or more peptides in a single stable lyophilized pharmaceutical compound |
| 05/20/2010 | WO2010054440A1 Bmp-7 compounds for modulating the expression of telomerase reverse transcriptase |
| 05/20/2010 | WO2010035259A3 Compositions comprising soluble cd84 or anti-cd84 antibodies and methods for diagnosing and treating b-cll |
| 05/20/2010 | WO2010034032A3 Methods for preparing purified polypeptide compositions |
| 05/20/2010 | WO2010030790A3 Methods and compositions for stimulation of mammalian innate immune resistance to pathogens |
| 05/20/2010 | WO2010030314A3 Aberrant expression of cks1 and cks2 and uses thereof |
| 05/20/2010 | WO2010022017A3 Method and composition for enhancing hematopoietic stem cell mobilization |
| 05/20/2010 | WO2010017369A3 Macromolecular diffusion and release from self-assembled b-hairpin peptide hydrogels |
| 05/20/2010 | WO2010014946A3 Halogen-stabilized insulin |
| 05/20/2010 | WO2010011315A3 Proteins for use in diagnosing and treating infection and disease |
| 05/20/2010 | WO2010003002A9 Modulation of follicular helper t cells |
| 05/20/2010 | WO2009149931A3 Fatty acid binding protein in the pathogenesis of cardiac dysfunction |
| 05/20/2010 | WO2009124971A3 Novel compositions and their use |
| 05/20/2010 | WO2009098577A3 Non-immunosuppressive cyclosporin for the treatment of muscular dystrophy |
| 05/20/2010 | WO2009083663A8 Cyclic peptides comprising at least one aza-β3-aminoacyl residue and uses thereof |
| 05/20/2010 | WO2009033588A3 Self-controlled insulin delivery system |
| 05/20/2010 | US20100125918 Enterovirus type 71 protein and method for production |
| 05/20/2010 | US20100125130 Tumour necrosis factor binding ligands |
| 05/20/2010 | US20100125127 Activation antigen expressed on B-cells for treating conditions associated with aberrant or increased T-cell proliferation |
| 05/20/2010 | US20100125056 Crystalline form of linaclotide |
| 05/20/2010 | US20100125055 Muc-1 cytoplasmic domain peptides as inhibitors of cancer |
| 05/20/2010 | US20100125054 Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders |
| 05/20/2010 | US20100125053 Allosteric Modulation of the Dopamine Transporter Protein for the Treatment of HIV-1 Induced Neurologic Dysfunction |
| 05/20/2010 | US20100125052 Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
| 05/20/2010 | US20100125051 Parenteral Formulations Comprising Sugar-Based Esters and Ethers |
| 05/20/2010 | US20100125050 Process for the Manufacture of Eptifibatide |
| 05/20/2010 | US20100125049 Polymer factor viii moiety conjugates |
| 05/20/2010 | US20100124566 Protection against and treatment of ionizing radiation |
| 05/20/2010 | US20100124554 Redox-active compounds and related compounds, compositions, methods and systems |
| 05/20/2010 | US20100124553 Methods for Treatment of HIV and Other Infections Using A T Cell or Viral Activator and Anti-Retroviral Combination Therapy |
| 05/20/2010 | US20100124549 Composition and Method for Treatment of Bruising |
| 05/20/2010 | US20100124548 Pharmaceutical product |
| 05/20/2010 | US20100124545 Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus |
| 05/20/2010 | US20100124544 Crystalline forms of dihydropyrazolopyrimidinone |
| 05/20/2010 | US20100124543 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors |
| 05/20/2010 | US20100124541 Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv |
| 05/20/2010 | US20100124536 Hemophilia Treatment by Inhalation of Coagulation Factors |
| 05/20/2010 | DE102008037564A1 Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden Composition for the production of anti-amyloid beta-peptide antibodies with peptides D- |
| 05/20/2010 | CA2780624A1 Isoprenyl compounds and methods thereof |
| 05/20/2010 | CA2743789A1 Low viscosity highly concentrated suspensions |
| 05/20/2010 | CA2743610A1 Fibroblast growth factor-9 promotes hair follicle regeneration after wounding |
| 05/20/2010 | CA2743502A1 Foxp3+ natural killer t-cells and the treatment of immune related diseases |
| 05/20/2010 | CA2743496A1 Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
| 05/20/2010 | CA2743464A1 Therapeutic and diagnostic methods relating to cancer stem cells |
| 05/20/2010 | CA2743394A1 Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases |
| 05/20/2010 | CA2743145A1 Azepinone derivatives |
| 05/20/2010 | CA2743141A1 Compositions and methods of use for soluble thrombomodulin variants |
| 05/20/2010 | CA2742871A1 Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
| 05/20/2010 | CA2741929A1 Suppression of cancer |
| 05/19/2010 | EP2186902A2 Medical preparations for the treatment of alpha-galactosidase a deficiency |
| 05/19/2010 | EP2186901A2 Mutations in the BCR-Abl-tyrosine kinase associated with resistance to STI-571 |
| 05/19/2010 | EP2186896A1 Cancer antigen peptides derived from WT1 |
| 05/19/2010 | EP2186889A1 Cdca1 peptide and pharmaceutical agent comprising the same |
| 05/19/2010 | EP2186888A1 Transgenic non-human animals capable of producing heterologous antibodies |
| 05/19/2010 | EP2186877A2 Cytokine concentration system |
| 05/19/2010 | EP2186830A1 Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof |
| 05/19/2010 | EP2186826A1 Chimeric hirudin proteins |
| 05/19/2010 | EP2186824A2 Chronic treatment regimen using glucagon-like insulinotropic peptides |
| 05/19/2010 | EP2186822A1 Use of inhibitors of Plac8 activity for the modulation of adipogenesis |
| 05/19/2010 | EP2186821A1 Protein with promoting effects for axonal growth of neurons of central nervous system |
| 05/19/2010 | EP2186820A1 Protein-protein interactions in human immunodeficiency virus |
| 05/19/2010 | EP2186525A2 G-CSF for use in the treatment of Parkinson's disease |
| 05/19/2010 | EP2186524A1 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| 05/19/2010 | EP2185719A2 Anti-rantes antibodies and methods of use thereof |
| 05/19/2010 | EP2185707A2 Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same |
| 05/19/2010 | EP2185588A1 Synthetic pulmonary surfactant peptides |
| 05/19/2010 | EP2185586A1 Immune modulation via c-type lectin |
| 05/19/2010 | EP2185585A1 Leptin fusion proteins |
| 05/19/2010 | EP2185584A1 Interferon fusion proteins |
| 05/19/2010 | EP2185582A2 Erythropoietin fusion proteins |
| 05/19/2010 | EP2185580A1 Lactation-associated polypeptides |
| 05/19/2010 | EP2185202A1 Use of interleukin-22 in the treatment of fatty liver disease |
| 05/19/2010 | EP2185200A2 Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue |
| 05/19/2010 | EP2185197A1 Novel cellular factor- containing solution compositions |
| 05/19/2010 | EP2185187A1 Subcutaneous administration of alpha-galatosidase a |
| 05/19/2010 | EP2185186A2 Compound and device for treating bone and/or cartilage defects |
| 05/19/2010 | EP2185185A2 Variegin from amblyomma variegatum is a direct thrombin inhibitor |
| 05/19/2010 | EP2185183A2 Use of natriuretic peptides for treating angioedema syndromes |
| 05/19/2010 | EP2185181A2 Therapeutic uses of gastrin-1 and g-pen-grgdspca |
| 05/19/2010 | EP2185180A1 Big gastrin i as a therapeutic agent |
| 05/19/2010 | EP2185177A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent |
| 05/19/2010 | EP2185176A2 Vhz for diagnosis and treatment of cancer |
| 05/19/2010 | EP2185174A1 Use of trim72 as a target for muscle and heart enhancer |
| 05/19/2010 | EP2185173A1 Use of phosphatases to treat neuroblastomas and medullogastomas |
| 05/19/2010 | EP2185172A2 Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection |
| 05/19/2010 | EP2185171A2 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents |
| 05/19/2010 | EP2185170A1 Composition for long-acting peptide analogs |
| 05/19/2010 | EP2185159A2 Bortezomib and process for producing same |
| 05/19/2010 | EP2185101A2 Fertilisation protein |